Future directions in pharmacogenomics discovery in cardiovascular disease

Pharmacogenomics. 2018 Apr;19(5):375-377. doi: 10.2217/pgs-2018-0002. Epub 2018 Mar 23.

Authors

Kevin A Friede¹, Deepak Voora^{1

2}

Affiliations

¹ Division of Cardiology, Duke University, Durham, NC 27710, USA.
² Duke Center for Applied Genomics & Precision Medicine, Duke University, Durham, NC 27708, USA.

PMID: 29569527
DOI: 10.2217/pgs-2018-0002

No abstract available

Keywords: coronary artery disease; pharmacogenomics.

Publication types

Editorial
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

Anti-HIV Agents / adverse effects
Anti-HIV Agents / therapeutic use
Cardiovascular Diseases / drug therapy*
Cardiovascular Diseases / genetics*
Dideoxynucleosides / adverse effects
Dideoxynucleosides / therapeutic use
Drug Hypersensitivity / genetics
Forecasting
Genome-Wide Association Study
Humans
Pharmacogenetics / trends*

Substances

Anti-HIV Agents
Dideoxynucleosides
abacavir